Emily Bell
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Emily Bell has a total of 30 co-authors. Here are the top co-authors by number of shared publications:
- Eric Racine
Institut de recherches cliniques de Montréal
7 shared publications Eric Racine
Neuroethics Research Unit, Institut de recherches cliniques de Montréal; Department of Medicine and Department of Social and Preventive Medicine, Université de Montréal; and Departments of Neurology and Neurosurgery, Experimental Medicine, McGill University
6 shared publicationsNina Di Pietro
National Core for Neuroethics, University of British Columbia
2 shared publicationsAbbas Sadikot
Montreal Neurological Institute
1 shared publicationAlbert E. Chudley
Department of Pediatrics, University of Manitoba
1 shared publicationAnne Synnes
University of British Columbia, Vancouver, British Columbia, Canada
1 shared publication
Latest Publications
- 5 November 2015
- Published by Wiley in International Journal of Developmental Neuroscience
- Vol. 47 (Part_A) , 30
ISDN2014_0108: Examining the ethical challenges of screening for biomarkers of prenatal alcohol exposure
- 5 November 2015
- Published by Wiley in International Journal of Developmental Neuroscience
- Vol. 47 (Part_A) , 30
ISDN2014_0108: Examining the ethical challenges of screening for biomarkers of prenatal alcohol exposure
- Open Access
- 18 May 2015
- Published by Oxford University Press (OUP) in Public Health Ethics
- Vol. 9 (1) , 65-77
It’s a Shame! Stigma Against Fetal Alcohol Spectrum Disorder: Examining the Ethical Implications for Public Health Practices and Policies
Stigma can influence the prevention and identification of fetal alcohol spectrum disorder (FASD), a leading cause of developmental delay in North America. Understanding the effects of public health practices and policies on stigma is imperative. We reviewed social science and biomedical literatures to understand the nature of stigma in FASD and its relevance from an ethics standpoint in matters of health practices and policies (e.g., diagnostic practices, awareness campaigns). We propose (i) a descriptive model of stigma in FASD and note current knowledge gaps; (ii) discuss the ethical implications of stigma based on two distinct criteria (dignity and consequences); and (iii) describe two cases and the concerns associated with inadvertent stigmatization by public health initiatives for FASD. We recommend further empirical and ethical analyses to examine whether public health policies and practices inadvertently stigmatize and impact the success of public health initiatives and programs for FASD.
- 18 May 2015
- Published by Oxford University Press (OUP) in Public Health Ethics
- Vol. 9 (1) , 65-77
Open AccessIt’s a Shame! Stigma Against Fetal Alcohol Spectrum Disorder: Examining the Ethical Implications for Public Health Practices and Policies
Stigma can influence the prevention and identification of fetal alcohol spectrum disorder (FASD), a leading cause of developmental delay in North America. Understanding the effects of public health practices and policies on stigma is imperative. We reviewed social science and biomedical literatures to understand the nature of stigma in FASD and its relevance from an ethics standpoint in matters of health practices and policies (e.g., diagnostic practices, awareness campaigns). We propose (i) a descriptive model of stigma in FASD and note current knowledge gaps; (ii) discuss the ethical implications of stigma based on two distinct criteria (dignity and consequences); and (iii) describe two cases and the concerns associated with inadvertent stigmatization by public health initiatives for FASD. We recommend further empirical and ethical analyses to examine whether public health policies and practices inadvertently stigmatize and impact the success of public health initiatives and programs for FASD.
- 1 May 2014
- Published by SAGE Publications in Journal of Child Neurology
- Vol. 30 (2) , 174-181
Magnetic Resonance Imaging (MRI) and Prognostication in Neonatal Hypoxic-Ischemic Injury
Magnetic resonance imaging (MRI) could improve prognostication in neonatal brain injury; however, factors beyond technical or scientific refinement may impact its use and interpretation. We surveyed Canadian neonatologists and pediatric neurologists using general and vignette-based questions about the use of MRI for prognostication in neonates with hypoxic-ischemic injury. There was inter- and intra-vignette variability in prognosis and in ratings about the usefulness of MRI. Severity of predicted outcome correlated with certainty about the outcome. A majority of physicians endorsed using MRI results in discussing prognosis with families, and most suggested that MRI results contribute to end-of-life decisions. Participating neonatologists, when compared to participating pediatric neurologists, had significantly less confidence in the interpretation of MRI by colleagues in neurology and radiology. Further investigation is needed to understand the complexity of MRI and of its application. Potential gaps relative to our understanding of the ethical importance of these findings should be addressed.
- 1 May 2014
- Published by SAGE Publications in Journal of Child Neurology
- Vol. 30 (2) , 174-181
Magnetic Resonance Imaging (MRI) and Prognostication in Neonatal Hypoxic-Ischemic Injury
Magnetic resonance imaging (MRI) could improve prognostication in neonatal brain injury; however, factors beyond technical or scientific refinement may impact its use and interpretation. We surveyed Canadian neonatologists and pediatric neurologists using general and vignette-based questions about the use of MRI for prognostication in neonates with hypoxic-ischemic injury. There was inter- and intra-vignette variability in prognosis and in ratings about the usefulness of MRI. Severity of predicted outcome correlated with certainty about the outcome. A majority of physicians endorsed using MRI results in discussing prognosis with families, and most suggested that MRI results contribute to end-of-life decisions. Participating neonatologists, when compared to participating pediatric neurologists, had significantly less confidence in the interpretation of MRI by colleagues in neurology and radiology. Further investigation is needed to understand the complexity of MRI and of its application. Potential gaps relative to our understanding of the ethical importance of these findings should be addressed.
- 3 May 2013
- Published by Taylor & Francis in The American Journal of Bioethics
- Vol. 13 (6) , 18-9
Nudging without ethical fudging: clarifying physician obligations to avoid ethical compromise.
- 3 May 2013
- Published by Taylor & Francis in The American Journal of Bioethics
- Vol. 13 (6) , 18-9
Nudging without ethical fudging: clarifying physician obligations to avoid ethical compromise.
- 2 April 2013
- Published by Wiley in Alcohol, Clinical and Experimental Research
- Vol. 37 (9) , 1451-1455
Comments and Reflections on Ethics in Screening for Biomarkers of Prenatal Alcohol Exposure
Early identification of and intervention for fetal alcohol spectrum disorder (FASD) has been shown to optimize outcomes for affected individuals. Detecting biomarkers of prenatal alcohol exposure (PAE) in neonates may assist in the identification of children at risk of FASD enabling targeted early interventions. Despite these potential benefits, complicated ethical issues arise in screening for biomarkers of PAE and these must be addressed prior to the implementation of screening programs. Here, we identify and comment, based on a North American perspective, on concerns raised in the current ethical, social, and legal literature related to meconium screening for PAE. Major ethical concerns revolve around the targeting of populations for PAE screening, consent and respect for persons, stigma and participation rates, the cost-benefit analysis of a screening program, consequences of false-positive and false-negative test results, confidentiality and appropriate follow-up to positive screen results, and the use of screen results for criminal prosecution. We identify gaps in the literature on screening for PAE, most notably related to a lack of stakeholder perspectives (e.g., parents, healthcare providers) about screening and the ethical challenges it presents.
- 2 April 2013
- Published by Wiley in Alcohol, Clinical and Experimental Research
- Vol. 37 (9) , 1451-1455
Comments and Reflections on Ethics in Screening for Biomarkers of Prenatal Alcohol Exposure
Early identification of and intervention for fetal alcohol spectrum disorder (FASD) has been shown to optimize outcomes for affected individuals. Detecting biomarkers of prenatal alcohol exposure (PAE) in neonates may assist in the identification of children at risk of FASD enabling targeted early interventions. Despite these potential benefits, complicated ethical issues arise in screening for biomarkers of PAE and these must be addressed prior to the implementation of screening programs. Here, we identify and comment, based on a North American perspective, on concerns raised in the current ethical, social, and legal literature related to meconium screening for PAE. Major ethical concerns revolve around the targeting of populations for PAE screening, consent and respect for persons, stigma and participation rates, the cost-benefit analysis of a screening program, consequences of false-positive and false-negative test results, confidentiality and appropriate follow-up to positive screen results, and the use of screen results for criminal prosecution. We identify gaps in the literature on screening for PAE, most notably related to a lack of stakeholder perspectives (e.g., parents, healthcare providers) about screening and the ethical challenges it presents.
- 1 January 2013
- Vol. 35 (3) , 23-32
Clinical and ethical dimensions of an innovative approach for treating mental illness: a qualitative study of health care trainee perspectives on deep brain stimulation.
The acquisition of knowledge and application of critical thinking skills are required to tackle the clinical and ethical dimensions of new approaches and technologies. Health care trainees rely partly on their training to manage, reason and reflect on the ethical uncertainties of innovations and new technologies. Deep brain stimulation (DBS) is neurosurgery involving the implantation of electrodes into deep brain nuclei and is approved for Parkinson's disease and other motor disorders. Experimental uses of DBS are emerging in refractory obsessive compulsive disorder and depression. We conducted a qualitative interview-based study to gather the perspectives of health care trainees from different disciplines on the clinical and ethical issues associated with DBS in psychiatric disorders. First impressions about the use of DBS in mental illness were mixed. We identified factors influencing impressions about DBS and information missing that compounded uncertainty about long-term outcomes and effects on other physical or psychological systems. Participants revealed nascent exploration of the ethical issues of DBS. They emphasized the obligations of health care providers to manage ethical problems and supported patient autonomy in guiding choice, even when choosing innovative approaches. We discuss trainee expectations about evidence in decision making and the role of ethics education.
- 1 January 2013
- Vol. 35 (3) , 23-32
Clinical and ethical dimensions of an innovative approach for treating mental illness: a qualitative study of health care trainee perspectives on deep brain stimulation.
The acquisition of knowledge and application of critical thinking skills are required to tackle the clinical and ethical dimensions of new approaches and technologies. Health care trainees rely partly on their training to manage, reason and reflect on the ethical uncertainties of innovations and new technologies. Deep brain stimulation (DBS) is neurosurgery involving the implantation of electrodes into deep brain nuclei and is approved for Parkinson's disease and other motor disorders. Experimental uses of DBS are emerging in refractory obsessive compulsive disorder and depression. We conducted a qualitative interview-based study to gather the perspectives of health care trainees from different disciplines on the clinical and ethical issues associated with DBS in psychiatric disorders. First impressions about the use of DBS in mental illness were mixed. We identified factors influencing impressions about DBS and information missing that compounded uncertainty about long-term outcomes and effects on other physical or psychological systems. Participants revealed nascent exploration of the ethical issues of DBS. They emphasized the obligations of health care providers to manage ethical problems and supported patient autonomy in guiding choice, even when choosing innovative approaches. We discuss trainee expectations about evidence in decision making and the role of ethics education.
- 13 September 2012
- Published by Springer Nature
- p. 273-288
Ethical Guidance for the Use of Deep Brain Stimulation in Psychiatric Trials and Emerging Uses: Review and Reflections
- 13 September 2012
- Published by Springer Nature
- p. 273-288
Ethical Guidance for the Use of Deep Brain Stimulation in Psychiatric Trials and Emerging Uses: Review and Reflections
- Open Access
- 14 January 2011
- Published by Springer Nature in BMC Medical Ethics
- Vol. 12 (1) , 1
Informed consent for MRI and fMRI research: Analysis of a sample of Canadian consent documents
Background: Research ethics and the measures deployed to ensure ethical oversight of research (e.g., informed consent forms, ethics review) are vested with extremely important ethical and practical goals. Accordingly, these measures need to function effectively in real-world research and to follow high level standards. Methods: We examined approved consent forms for Magnetic Resonance Imaging (MRI) and functional Magnetic Resonance Imaging (fMRI) studies approved by Canadian research ethics boards (REBs). Results: We found evidence of variability in consent forms in matters of physical and psychological risk reporting. Approaches used to tackle the emerging issue of incidental findings exposed extensive variability between and within research sites. Conclusion: The causes of variability in approved consent forms and studies need to be better understood. However, mounting evidence of administrative and practical hurdles within current ethics governance systems combined with potential sub-optimal provision of information to and protection of research subjects support other calls for more scrutiny of research ethics practices and applicable revisions.
- 14 January 2011
- Published by Springer Nature in BMC Medical Ethics
- Vol. 12 (1) , 1
Open AccessInformed consent for MRI and fMRI research: Analysis of a sample of Canadian consent documents
Background: Research ethics and the measures deployed to ensure ethical oversight of research (e.g., informed consent forms, ethics review) are vested with extremely important ethical and practical goals. Accordingly, these measures need to function effectively in real-world research and to follow high level standards. Methods: We examined approved consent forms for Magnetic Resonance Imaging (MRI) and functional Magnetic Resonance Imaging (fMRI) studies approved by Canadian research ethics boards (REBs). Results: We found evidence of variability in consent forms in matters of physical and psychological risk reporting. Approaches used to tackle the emerging issue of incidental findings exposed extensive variability between and within research sites. Conclusion: The causes of variability in approved consent forms and studies need to be better understood. However, mounting evidence of administrative and practical hurdles within current ethics governance systems combined with potential sub-optimal provision of information to and protection of research subjects support other calls for more scrutiny of research ethics practices and applicable revisions.
- 13 January 2011
- Published by Taylor & Francis in AJOB Neuroscience
- Vol. 2 (1) , 16-18
Subjective Outcomes Measurement and Regulatory Oversight for Deep Brain Stimulation in Parkinson's Disease
- 13 January 2011
- Published by Taylor & Francis in AJOB Neuroscience
- Vol. 2 (1) , 16-18
Subjective Outcomes Measurement and Regulatory Oversight for Deep Brain Stimulation in Parkinson's Disease
- 2 July 2010
- Vol. 32 (3) , 12-8
Canadian research ethics boards and multisite research: experiences from two minimal-risk studies.
- 2 July 2010
- Vol. 32 (3) , 12-8
Canadian research ethics boards and multisite research: experiences from two minimal-risk studies.